136 related articles for article (PubMed ID: 38266131)
1. Anti-IL-5 and anti-IL-5R biologics for severe asthma. Are there any differences in their effects?
Granda P; Villamañán E; Carpio C; Laorden D; Quirce S; Álvarez-Sala R;
J Asthma; 2024 Jan; ():1-10. PubMed ID: 38266131
[TBL] [Abstract][Full Text] [Related]
2. Anti-IL-5 therapies for asthma.
Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
4. Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts.
Ghassemian A; Park JJ; Tsoulis MW; Kim H
Allergy Asthma Clin Immunol; 2021 Jan; 17(1):3. PubMed ID: 33407869
[TBL] [Abstract][Full Text] [Related]
5. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
6. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study).
Martínez-Moragón E; García-Moguel I; Nuevo J; Resler G;
BMC Pulm Med; 2021 Dec; 21(1):417. PubMed ID: 34922515
[TBL] [Abstract][Full Text] [Related]
7. Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.
Scioscia G; Tondo P; Nolasco S; Pelaia C; Carpagnano GE; Caiaffa MF; Valenti G; Maglio A; Papia F; Triggiani M; Crimi N; Pelaia G; Vatrella A; Foschino Barbaro MP; Crimi C
J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445397
[TBL] [Abstract][Full Text] [Related]
8. Exploring the risk of infection events in patients with asthma receiving
Giossi R; Pani A; Schroeder J; Scaglione F
Heliyon; 2024 Jan; 10(1):e23725. PubMed ID: 38268596
[TBL] [Abstract][Full Text] [Related]
9. Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma.
Drick N; Milger K; Seeliger B; Fuge J; Korn S; Buhl R; Schuhmann M; Herth F; Kendziora B; Behr J; Kneidinger N; Bergmann KC; Taube C; Welte T; Suhling H
J Asthma Allergy; 2020; 13():605-614. PubMed ID: 33204117
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma.
AlShareef S; McDonald CF; Lee J
J Asthma Allergy; 2022; 15():209-217. PubMed ID: 35210787
[TBL] [Abstract][Full Text] [Related]
12. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
[TBL] [Abstract][Full Text] [Related]
13. Overall Response to Anti-IL-5/Anti-IL5-Rα Treatment in Severe Asthma Does Not Depend on Initial Bronchodilator Responsiveness.
Mümmler C; Suhling H; Walter J; Kneidinger N; Buhl R; Kayser MZ; Drick N; Behr J; Welte T; Korn S; Milger K
J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3174-3183. PubMed ID: 35870725
[TBL] [Abstract][Full Text] [Related]
14. Anti-IL-4R versus Anti-IL-5/5R after Anti-IL-5/5R failure in asthma: an emulated target trial.
Valery S; Simon-Tillaux N; Devouassoux G; Bonniaud P; Beurnier A; Boudjemaa A; Chenivesse C; Bourdin A; Gauquelin L; Guillo S; Taillé C; Estellat C;
J Allergy Clin Immunol; 2024 Jun; ():. PubMed ID: 38848878
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
[TBL] [Abstract][Full Text] [Related]
16. Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study.
Rojo-Tolosa S; González-Gutiérrez MV; Jiménez-Gálvez G; Sánchez-Martínez JA; Pineda-Lancheros LE; Gálvez-Navas JM; Jiménez-Morales A; Pérez-Ramírez C; Morales-García C
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768331
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients.
Valverde-Monge M; Sánchez-Carrasco P; Betancor D; Barroso B; Rodrigo-Muñoz JM; Mahillo-Fernández I; Arismendi E; Bobolea I; Cárdaba B; Cruz MJ; Del Pozo V; Domínguez-Ortega J; González-Barcala FJ; Olaguibel JM; Luna-Porta JA; Martínez-Rivera C; Mullol J; Muñoz X; Peleteiro-Pedraza L; Picado Valles C; Plaza V; Quirce S; Rial MJ; Soto-Retes L; Valero A; Sastre J
Arch Bronconeumol; 2024 Jan; 60(1):23-32. PubMed ID: 38042707
[TBL] [Abstract][Full Text] [Related]
18. A pragmatic guide to choosing biologic therapies in severe asthma.
Kavanagh JE; Hearn AP; Jackson DJ
Breathe (Sheff); 2021 Dec; 17(4):210144. PubMed ID: 35296105
[TBL] [Abstract][Full Text] [Related]
19. Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease.
Wangberg H; Spierling Bagsic SR; Osuna L; White AA
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):478-484.e3. PubMed ID: 34597850
[TBL] [Abstract][Full Text] [Related]
20. [The Effectiveness of Mepolizumab and Benralizumab in a Real-Life Cohort of Patients with Severe Eosinophilic Asthma].
Espinosa de Los Monteros Garde MJ; Romero Sanz V; Blázquez Romero C
Open Respir Arch; 2021; 3(2):100103. PubMed ID: 37497072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]